Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Korea Bans 1,100 Drugs And Vitamins During Probe Into Asbestos

This article was originally published in The Tan Sheet

  • News
  • Peter Chang

Executive Summary

South Korea ordered 120 manufacturers of vitamins and OTC and generic drugs to recall 1,122 products made with talc suspected of containing asbestos

You may also be interested in...



FDA Surveys Cosmetic Products For Asbestos-Contaminated Talc

FDA is reviewing talc and talc-containing cosmetic products for asbestos contamination following reports of the carcinogen in cosmetics overseas

FDA Surveys Cosmetic Products For Asbestos-Contaminated Talc

FDA is reviewing talc and talc-containing cosmetic products for asbestos contamination following reports of the carcinogen in cosmetics overseas

FDA Surveys Cosmetic Products For Asbestos-Contaminated Talc

FDA is reviewing talc and talc-containing cosmetic products for asbestos contamination following reports of the carcinogen in cosmetics overseas

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS102825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By